Purpose: The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM) in patients with overactive bladder (OAB).
Methods: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient's request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM. The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM. Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation.
Results: The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017).
Conclusion: The treatment effect achieved during the initial phase of peroneal eTNM persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00345-023-04394-z | DOI Listing |
Neurourol Urodyn
August 2023
Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Objectives: To compare brain responses to peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) and transcutaneous tibial nerve stimulation (TTNS), two methods for treating overactive bladder (OAB), using functional magnetic resonance imaging (fMRI). The present study was not designed to compare their clinical efficacy.
Materials And Methods: This study included 32 healthy adult female volunteers (average age 38.
World J Urol
June 2023
Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Purpose: The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM) in patients with overactive bladder (OAB).
Methods: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months.
Int Urogynecol J
June 2023
Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Introduction And Hypothesis: The aim of this prospective, open-label, multicenter, noncomparative study was to evaluate the efficacy and safety of peroneal electrical transcutaneous neuromodulation (peroneal eTNM) using the URIS neuromodulation system as a home treatment for refractory overactive bladder (OAB).
Methods: The patients were treated with daily peroneal eTNM for 30 min over a 6-week period. The primary endpoint was defined as the proportion of responders, i.
Urol Int
July 2022
Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Introduction: The aim of this study was to determine whether peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) using the URIS® neuromodulation system can be used in individuals with refractory overactive bladder (OAB).
Methods: Eighteen female patients with idiopathic OAB who failed previous behavioral and pharmacological therapy were enrolled. Patients were treated with the URIS® neuromodulation system using active electrodes placed on the popliteal fossa, targeting the peroneal nerve for 30 min once a week for 12 weeks.
J Healthc Eng
December 2021
Biomedical Laboratory and Research Unit of Urology Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Overactive bladder syndrome (OAB) is a prevalent medical problem with a significant impact on the quality of life of the affected individuals. Pharmacotherapy is considered the main treatment method, although it is discontinued in a significant proportion of patients due to inefficacy or associated side effects. If pharmacotherapy fails, patients can undergo peripheral neuromodulation of the somatic nerves of the lower limb or sacral neuromodulation; however, neither of these represents an ideal therapeutic tool.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!